Led · Equity · Sep 2025

Centros Torguet operates 18 psychology clinics across Spain, delivering mental-health services through two business lines: private patients and patients referred by major insurers. Founded by entrepreneur Maurici Badia and psychologist Mercè Torguet, the company seeks to combine high-quality in-person therapy with a seamless digital experience. Revenues grew from €300,000 in 2023 to €830,000 in 2024, with a forecast of €1.3 million for 2025. Current sites include Barcelona, Girona, Tarragona, Lleida, Alicante, Bilbao, A Coruña and Murcia. The firm plans to relocate to larger premises in its existing nine cities and open clinics in ten additional cities. It will also launch a new website and booking platform, strengthen its call center, and invest in brand-building marketing. By 2027, Centros Torguet aims to run 50 clinics and become Spain’s leading psychology network.

Participated · Equity · Oct 2023

ADmit Therapeutics is a biotechnology spin‑off from the Instituto de Investigación Biomédica de Bellvitge (IDIBELL), founded in late 2017. The company develops MAP‑AD, a blood‑based diagnostic that uses an algorithm to stratify patients with mild cognitive impairment (MCI) by their probability of progression to Alzheimer’s disease through epigenetic analysis of mitochondrial DNA methylation signatures. Its approach combines patented biomarker patterns and a novel algorithm to link methylation patterns with clinical prognosis. ADmit positions MAP‑AD as a tool for clinicians to optimize patient stratification and for pharmaceutical companies to improve selection in clinical trials, potentially reducing time and costs. The company plans to use the recent financing to obtain CE marking and FDA approval to commercialize MAP‑AD in Europe and the United States. Marta Barrachina is cited as CEO leading the team and scientific capabilities behind the technology. ADmit Therapeutics, a spin‑off from IDIBELL founded in late 2017, is developing a blood test for early detection of Alzheimer’s based on epigenetic analysis of mitochondrial DNA. The company’s approach rests on the hypothesis that mitochondrial dysfunction precedes the appearance of amyloid and tau aggregates, creating a diagnostic window before clinical decline. ADmit is training a predictive algorithm on more than 300 blood samples and planned to begin clinical validation the year after the article (2021). Its near‑term regulatory goal is to obtain CE marking and reach the market by 2023. The team is led by CEO and co‑founder Marta Barrachina, with clinical co‑founders and advisers Ramón Reñé and Jordi Gascón. Financially, ADmit has accumulated multiple funding sources including grants, equity crowdfunding and private investments, totaling nearly €5 million in under three years. ADmit Therapeutics develops an in vitro early diagnostic test for Alzheimer's disease using blood samples, plus an associated predictive algorithm and software for patient diagnosis. The company is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL) and was founded in late 2017. It has received national and European grants and private investments from backers including Ship2B, GENESIS Biomed and BStartup10. ADmit aims to obtain a CE mark in 2023 to commercialize its diagnostic algorithm and software. The business is pursuing clinical validation funding and is participating in impact acceleration programs such as S2B Tech4Health. ADmit Therapeutics develops an early diagnostic test for Alzheimer’s disease and is working toward a laboratory IVD device intended to obtain CE marking by late 2022. The company plans to use recent funding to advance its diagnostic development, begin clinical validation, and secure commercial partner agreements. Management says the test could optimize patient recruitment for clinical trials and improve the chances of demonstrating drug efficacy. The company intends to valorize its clinical proof of concept and reinforce its intellectual property with the new funds. ADmit operates in the biotechnology/genetic engineering sector and is based in L'Hospitalet de Llobregat (Barcelona).

Participated · Equity · Aug 2023

Dental Residency provides domiciliary dental services to people with mobility problems, delivering care in nursing homes and day centres. The company currently serves more than 1,000 residences and day centres in Spain and has treated over 90,000 patients. In the first half of the year it reported a 75% increase in billing and projects 100% growth by year-end. Funds raised will be used to scale services in Spain and to accelerate international expansion. Dental Residency entered the Italian market in January with an operational centre in Milan, plans to open a centre in London in Q4 2023, and intends to enter Germany in 2024. Management aims to multiply the company’s European business fourfold within two years. Dental Residency delivers at‑home dental care using portable equipment and a specific methodology for dependent, institutionalized and mobility‑impaired patients. Since beginning operations in 2015 it has treated nearly 50,000 patients and serves more than 600 residences and day centers. The company currently operates in Catalonia and the Valencian Community and reached positive EBITDA in early 2021. Management projects to triple 2020 revenues by the end of 2021 and to increase them tenfold in 2022. Its expansion plan targets opening in eight new provinces in the first phase (starting in October) and reaching roughly 30 provinces by the end of 2022, with a goal to cover close to 95% of Spanish territory within two years. After consolidating the national expansion, the company aims to begin internationalization in 2023. Dental Residency provides domiciliary dental services to dependent institutionalized people using portable dental equipment to guarantee oral health when residents cannot travel to clinics. The company has operated in Catalonia, the Community of Madrid and the Valencian Community. It has served 600 residences and delivered annual oral-health reviews to more than 40,000 dependent people. With the new capital, Dental Residency intends to continue its growth plan and open new centers in other Spanish regions, including the Basque Country and Aragón. Financially, the company closed a €500k venture capital/business angels round through La Bolsa Social, which adds to €300k obtained in 2018. Investors in the round included Pau Mariné, the Seligrat family, Ramalama Inversiones, Equity4Good and René de Jong. Dental Residency is a dental-services company focused on older adults, operating in care homes and a clinic in Leganés (Madrid). It currently works with roughly 400 care homes in Catalonia and will begin offering free check-ups to about 3,000 residents from its Madrid clinic. The company expects to exceed €1 million in revenue this year, roughly triple its 2017 revenue after a 65% sales increase in 2017. Raised funds will be used to reinforce its position in Catalonia and to start operations in the Basque Country and the Community of Madrid within the year. The business model centers on providing in-residence dental care to institutionalized elderly populations alongside clinic services. The company is based in Barcelona (Catalonia) and operates in the healthcare/medical sector focused on geriatric dental care.

Led · Seed · Apr 2021

Agrosingularity develops food‑industry ingredients made from the mermas (waste) of local fresh fruit and vegetable production, producing natural aromas, colors, plant fibers, proteins and replacements for artificial additives. The company operates a production Hub in Murcia, plans a second Hub in Navarra and expects a third international Hub in 2022, following a "glocal" manufacturing model that leverages local biodiversity. Its customers include food manufacturers and biotech firms, and it has a strategic partnership with Brenntag, working in Iberia and expanding into Italy. Founded in July 2019, Agrosingularity has commercialized around twenty products and is evolving its ingredient portfolio further. Financially, the company reported €100,000 revenue in 2020 and projected more than €1.5M for 2021, targeting recurring revenue of €10M within three years. The team has recently doubled headcount and strengthened business development, finance, operations and product roles to support scale and international expansion.

Participated · Series A · Jan 2021

Devicare develops Lit-Control, a non-surgical solution for kidney stones that pairs a urine pH measuring device with an application to adjust nutraceutical dosing. The device measures patients' urinary pH and sends data to the app, enabling telemetric management and dose adjustments of nutraceuticals sold under the Lit-Control brand. The company already commercializes its nutraceuticals in Spain, has an agreement with Diem Labs to explore the U.S. market, and expects to start selling the pH meter around 2022. In 2020 Devicare reported €1 million in revenue and expected 50% growth in the following year. Proceeds from the new financing will be used to refine the Lit-Control software. Devicare is based at the Parc de Recerca de la UAB in Cerdanyola, was founded in 2012, and has raised €12 million in public and private capital since inception. Devicare is a Cerdanyola del Vallès, Barcelona, Spain–based medical device company specializing in innovative home-care solutions for chronic patients. It is developing a patented sensor technology to measure biometrics in breath and body fluids, including blood, sweat, saliva and urine, for disease prevention and treatment. The company currently offers two product lines: Lit-Control for prevention and self-management of recurrent urinary diseases, and Tao-Control for self-management of patients taking anticoagulants. Devicare has signed a €2m participative loan from the Innova Global line by Avançsa, with an option to convert the investment into Series A stock in the mid-term. Proceeds will fund the strategic development and validation plan of new medical solutions under a Remote Patient Monitoring concept and the corresponding clinical studies and trials. The company intends to use these results to support expansion throughout European and North American markets. Devicare develops and remotely manages medical devices for the home care of chronic patients. It currently markets two Remote Patient Monitoring (RPM) products: Lit-Control, which prevents and controls recurrent urological diseases via urinary pH monitoring, and Tao-Control, which helps control INR levels for patients on oral anticoagulants. These solutions are built under the RPM concept to enable patients to actively participate in monitoring their disease. The products are placed on the market through agreements with pharmaceutical companies. The company received a €133K participation loan to consolidate sales of its in-home self-management medical products. Devicare develops innovative medical devices targeting chronic home care patients, operating under a Remote Patient Monitoring (RPM) model. Its product lines include Lit-Control® for prevention and self-management of recurring urinary diseases and Tao-Control® for self-management of patients on oral anticoagulants. The company is led by founder and CEO Rosendo Garganta and Xavier Peris, sales and marketing director. Devicare intends to use recent funding to consolidate the launch of clinical studies of its product lines in the Spanish market. In 2017 the company recorded €1.1m in revenue and employs a staff of 20 professionals. To date the company has raised a total of €4.5m.